On Monday, Mineralys Therapeutics Inc (NASDAQ: MLYS) opened higher 42.21% from the last session, before settling in for the closing price of $10.52. Price fluctuations for MLYS have ranged from $8.24 to $15.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -3.11% at the time writing. With a float of $24.58 million, this company’s outstanding shares have now reached $49.82 million.
Considering the fact that the conglomerate employs 51 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Mineralys Therapeutics Inc is 50.67%, while institutional ownership is 54.66%. The most recent insider transaction that took place on Jan 13 ’25, was worth 97,864. In this transaction CFO and Secretary of this company sold 10,757 shares at a rate of $9.10, taking the stock ownership to the 226,097 shares. Before that another transaction happened on Jan 13 ’25, when Company’s Chief Executive Officer sold 18,333 for $9.06, making the entire transaction worth $166,082. This insider now owns 877,608 shares in total.
Mineralys Therapeutics Inc (MLYS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -3.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.25% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Check out the current performance indicators for Mineralys Therapeutics Inc (MLYS). In the past quarter, the stock posted a quick ratio of 14.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.79 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Compared to the last year’s volume of 0.65 million, its volume of 3.35 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 80.95%. Additionally, its Average True Range was 1.29.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 66.86%, which indicates a significant increase from 66.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 161.74% in the past 14 days, which was higher than the 92.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.47, while its 200-day Moving Average is $12.04. Nevertheless, the first resistance level for the watch stands at $17.67 in the near term. At $20.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.46. If the price goes on to break the first support level at $12.88, it is likely to go to the next support level at $10.79. Should the price break the second support level, the third support level stands at $8.09.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
There are currently 49,836K shares outstanding in the company with a market cap of 745.54 million. Presently, the company’s annual sales total 0 K according to its annual income of -177,810 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -48,950 K.
